Last reviewed · How we verify
NCT06173466
Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone
Phase 4 trial testing Liposomal bupivacaine in Liver Cancer in 96 participants. Completed in 30 May 2024.
28 February 2024
Quick facts
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 96 |
| Start date | 15 December 2023 |
| Primary completion | 28 February 2024 |
| Estimated completion | 30 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Liposomal bupivacaine — full drug profile →
- Bupivacaine Hydrochloride combined with dexamethasone — full drug profile →
Conditions studied
- Liver Cancer — all drugs for Liver Cancer →
Sponsor
Zhejiang Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Liposomal bupivacaine is a novel long-acting local anesthetic approved by the FDA for postoperative analgesia because of its ability to significantly prolong the analgesic effect for up to 72 hours. Up to now, no study has demonstrated the effect of postoperative analgesia with liposomal bupivacaine by thoracic paravertebral block (TPVB). The aim of this study was to evaluate the efficacy of liposomal bupivacaine for pain management and recovery after liver resection. Methods: 96 patients were involved in this randomized, prospective, single-blind study. Patients with hepatocellular carcinoma who were undergoing liver resection were divided into two groups: liposome bupivacaine group (liposomal bupivacaine 133mg) and standard bupivacaine combined with dexamethasone group (standard bupivacaine 150mg and dexamethasone 5mg). Both groups were applied ultrasound guided TPVB. The primary outcome was the cumulative opioid consumptionfor 72 hours. Secodary outcomes included QoR-40 at 72 hours, pain visual analog scale (VAS) score area under the curve (AUC) from 6 hours to 3 months, sleep quality at 1 month and 3 months postoperatively. Adverse events and serious adverse events 3 months after TPVB were also recorded.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Integrating diagnosis and therapy in hepatocellular carcinoma: advances in nanotheranostics.
Shen J, Wen Y, Wu S, Tian W. · · 2026 · PMID 41958834 · DOI 10.3389/fbioe.2026.1793834
Verify or expand the search:
- PubMed search for NCT06173466
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liposomal bupivacaine
Trials testing the same drug.
- NCT06704698 — Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery · NA · recruiting
- NCT06575699 — Rectus Sheath Block for Analgesia After Gynecological Laparotomy · Phase 4 · completed
- NCT06575010 — Exparel v Dexamethasone in RCR · Phase 4 · enrolling by invitation
- NCT06569953 — Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chron · Phase 4 · recruiting
- NCT06405724 — Comparison of the Ultrasound-guided Paravertebral Nerve Block With Liposomal Bupivacaine Versus Ropivacaine for Post-Sur · Phase 3 · not yet recruiting
Other recruiting trials for Liver Cancer
Currently open trials in the same condition.
- NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
- NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
Other Zhejiang Cancer Hospital trials
Trials by the same sponsor.
- NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06173466 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06173466.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing